|Description||SAR-20347 is a dual inhibitor of JAK1 and tyrosine kinase 2 (TYK2) with IC50 values of 23 and 0.6 nM, respectively. It also exhibits slight inhibitory effects gainst JAK2 and JAK3.|
|B0084-007837||25 mg||$198||In stock|
|B0084-007837||50 mg||$368||In stock|
|Synonyms||2-(2-Chloro-6-fluorophenyl)-5-[[4-(4-morpholinylcarbonyl)phenyl]amino]-4-oxazolecarboxamide; SAR 20347; SAR20347|
Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rh...
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
IC50 Value: JAK1 (5.9 nM) and JAK2 (5.7 nM). Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nan...
PF-956980, a close analogue of Tofacitinib, is a JAK3-selective inhibitor used as an anti-inflammatory agent. Besides, some studies showed that PF-956980 striki...
As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduces cell viability in a subset of NHL cell lines, and induces apoptosis in BCR-signaling competent N...
SAR-20347 is a dual inhibitor of JAK1 and tyrosine kinase 2 (TYK2) with IC50 values of 23 and 0.6 nM, respectively. It also exhibits slight inhibitory effects g...
Oclacitinib, also called as PF-03394197, is a novel inhibitor of JAK family members (IC50= 10 - 99 nM) and JAK1-dependent cytokines involved in allergy, inflamm...
Atiprimod dihydrochloride is the dihydrochloride salt form of atiprimod, which is an orally bioavailable small molecule belonging to the azaspirane class of cat...